NCT07584317尚未招募不适用
Artificial Intelligence-Based Multimodal Data Integration for Tumor Microenvironment Analysis and Response Prediction in Hepatocellular Carcinoma Patients Undergoing TACE Combined With Immunotherapy and Targeted Therapy
Gao-jun Teng0 个研究点目标入组 1,170 人开始时间: 2026年5月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,170
研究概览
简要总结
This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in HCC.
详细描述
This study will integrate a retrospective cohort with a prospective observational cohort. Multimodal data will be collected in the prospective cohort to validate the AI-based imaging model developed from the retrospective cohort. In addition, advanced multi-omics technologies will be incorporated to characterize tumor heterogeneity and the immune microenvironment, thereby supporting early and precise guidance for TACE combined with immunotherapy and targeted therapy in HCC.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Retrospective Study Cohort 1.1 Inclusion Criteria Age ≥18 years; Patients with hepatocellular carcinoma confirmed by histopathology or clinical diagnosis; At least one intrahepatic lesion that is repeatedly measurable according to RECIST v1.
排除标准
- •Known sarcomatoid hepatocellular carcinoma or fibrolamellar hepatocellular carcinoma; Presence of other active malignancies within the past 5 years or concurrent active malignancies other than hepatocellular carcinoma; Missing preoperative imaging examinations, including CT or MRI, or poor image quality; Missing key baseline clinical data; Loss to follow-up after treatment.
- •Prospective Study Cohort 2.1 Inclusion Criteria Age ≥18 years; Patients with hepatocellular carcinoma confirmed by histopathology or clinical diagnosis; Scheduled to receive first-line TACE combined with immunotherapy and targeted therapy; At least one intrahepatic lesion that is repeatedly measurable according to RECIST v1.1; Expected survival of more than 3 months. 2.2 Exclusion Criteria Known sarcomatoid hepatocellular carcinoma or fibrolamellar hepatocellular carcinoma; Presence of other active malignancies within the past 5 years or concurrent active malignancies other than hepatocellular carcinoma; Other factors that, in the investigator's judgment, make the patient unsuitable for participation in this study; Severe allergy to iodinated contrast agents that preclude imaging examinations or TACE treatment.
研究者
Gao-jun Teng
President
Zhongda Hospital
相似试验
招募中
不适用
A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in ChildrenNCT07375602Xinhua Hospital, Shanghai Jiao Tong University School of Medicine5,249
尚未招募
不适用
AI-Guided Intensified Follow-up After Surgery for Acute Type A Aortic DissectionNCT07623213Second Affiliated Hospital, School of Medicine, Zhejiang University1,314
招募中
不适用
AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)NCT07399236Tongji Hospital1,500
招募中
不适用
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）NSCLCNCT07388771Qian Chu500
尚未招募
不适用
Prospective Validation of an Artificial Intelligence Tool for Pre-Anesthetic AssessmentNCT07290647Hospital Nossa Senhora da Conceicao270